Who Owns Pentacel?
Pentacel is owned by Sanofi, a publicly traded French multinational pharmaceutical company. Pentacel is Sanofi's pentavalent combination vaccine. Sanofi is headquartered in Paris, France and trades on Euronext Paris (SNY).
Parent Company
Sanofi
Founded
2008
Status
Publicly Traded
Headquarters
Paris, France
Who Owns Pentacel?
- Parent Company: Sanofi
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: Euronext Paris: SNY
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Pentacel | Sanofi | Wholly owned |
History of Pentacel
- Founded: 2008
- Founders: Sanofi (internal development)
Pentacel's development began in the early 2000s when Sanofi Pasteur recognized the growing need for combination vaccines to reduce injection burden in pediatric immunization schedules. The vaccine represented an innovative approach to combine protection against five diseases (diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b) in a single formulation. After extensive clinical trials involving over 5,000 children across multiple countries, Pentacel received FDA approval in June 2008, becoming the first pentavalent combination vaccine approved in the United States.
The development process involved significant technological challenges in ensuring compatibility between the various antigens while maintaining efficacy and safety. Sanofi Pasteur's research teams in Toronto, Canada and Marcy l'Étoile, France collaborated on the formulation, which combined components from their existing vaccines. The DTaP-IPV component derived from Sanofi's DAPTACEL and IPOL vaccines, while the Hib component (ActHIB) was engineered to maintain stability in the combined formulation.
Following its 2008 introduction, Pentacel quickly gained adoption in pediatric practices across North America. By 2011, it had captured approximately 70% of the U.S. combination vaccine market for its indicated age group, becoming a standard component in the recommended childhood immunization schedule. The vaccine demonstrated substantial public health impact, with studies showing increased immunization schedule completion rates due to the reduced number of injections required.
In 2014, Sanofi implemented manufacturing process enhancements at its Toronto facility to increase production capacity by approximately 40%, responding to growing global demand. This expansion represented a significant investment in Pentacel's continued market position. Concurrently, the company initiated a comprehensive post-marketing surveillance program to monitor long-term safety and effectiveness data, which has since accumulated data from over 12 million administered doses.
A significant milestone occurred in 2018 when the FDA approved an extended shelf life for Pentacel from 24 to 36 months, improving inventory management for healthcare providers and reducing wastage. In 2020, amid the COVID-19 pandemic, Sanofi prioritized Pentacel production despite manufacturing disruptions, recognizing its essential role in maintaining childhood immunization rates during a public health crisis.
In 2022, Sanofi introduced a preservative-free formulation of Pentacel in response to evolving healthcare provider and parental preferences. This innovation required significant manufacturing process modifications while maintaining the vaccine's established safety and efficacy profile. The following year, Pentacel received approval for inclusion in additional national immunization programs in several middle-income countries, expanding its global footprint.
Most recently, in January 2026, Sanofi announced the completion of a comprehensive manufacturing technology transfer to its new vaccine production facility in Singapore, which will begin producing Pentacel for Asia-Pacific markets by mid-2026. This expansion represents Sanofi's commitment to ensuring global supply chain resilience for this critical pediatric vaccine. Concurrently, the company has initiated Phase 4 studies evaluating potential schedule optimizations and concomitant administration protocols with newer vaccines, ensuring Pentacel remains integrated effectively within evolving immunization recommendations.
About Sanofi
Sanofi is a French multinational pharmaceutical company founded in 1973, headquartered in Paris, France. Under new CEO Belén Garijo (appointed April 2026), Sanofi reported 2025 sales of €43.63 billion with 9.9% growth, driven by the success of Dupixent. The company trades on Euronext Paris (SNY) and operates globally with approximately 100,000 employees across primary care, specialty care, vaccines, and consumer healthcare divisions.
- Founded: 1973
- Headquarters: Paris, France
- Company Type: Publicly Traded
- Stock: Euronext Paris: SNY
- Revenue: €43.63 billion (FY2025)
- Employees: Approximately 100,000
Where Is Pentacel Made / Based?
- Headquarters: Paris, France
- Manufacturing / Operations: France, United States, Germany, Belgium
Pentacel Sustainability & Ethics
Pentacel operates within Sanofi's comprehensive sustainability framework, which addresses environmental responsibility, ethical business practices, and social impact across the global pharmaceutical industry. As a preventive healthcare vaccine, Pentacel's sustainability efforts focus on global immunization access, responsible manufacturing, and public health impact in the competitive vaccine market.
Global Immunization Access: Pentacel contributes to global health sustainability by providing comprehensive protection against five serious diseases in a single vaccine, reducing the need for multiple injections and healthcare visits. The vaccine's combination approach supports efficient immunization programs and reduces healthcare resource requirements in both developed and developing markets.
Responsible Manufacturing Practices: Pentacel is manufactured using Sanofi's sustainable manufacturing processes that include energy-efficient production facilities, waste reduction programs, and environmental compliance systems. The vaccine's manufacturing follows strict environmental standards while maintaining product quality and safety for global distribution.
Cold Chain Logistics Optimization: Pentacel's distribution requires cold chain logistics that have been optimized for environmental efficiency, including temperature-controlled shipping methods, route optimization to reduce transportation emissions, and partnerships with logistics providers committed to sustainable transportation practices.
Public Health Impact and Prevention: Pentacel's preventive healthcare approach contributes to sustainability by reducing the incidence of vaccine-preventable diseases, lowering healthcare costs associated with disease treatment, and supporting healthier communities. The vaccine's public health impact extends beyond individual protection to community-level disease prevention.
Regulatory Compliance and Safety: Pentacel maintains the highest standards of regulatory compliance and safety monitoring across all markets where it is distributed. The vaccine's safety surveillance programs include ongoing monitoring of adverse events, quality control systems, and transparent reporting to regulatory authorities and healthcare providers.
Ethical Pricing and Access: Sanofi implements ethical pricing strategies for Pentacel that balance innovation recovery with accessibility, particularly in developing markets where vaccine access is critical. The company's pricing approach includes tiered pricing strategies and partnerships with global health organizations to improve vaccine accessibility.
Health Equity and Social Responsibility: Pentacel supports health equity initiatives through partnerships with vaccination programs, public health organizations, and community immunization efforts. The vaccine's contribution to reducing health disparities aligns with broader social responsibility goals in global healthcare.
Awards & Recognition
Pentacel has received recognition within the pharmaceutical and healthcare industries for its innovative combination vaccine approach, contribution to preventive healthcare, and advancements in pediatric immunization. The vaccine's ability to protect against multiple diseases with a single formulation has been acknowledged as demonstrating excellence in vaccine development and public health innovation.
Vaccine Innovation Recognition: Pentacel has been acknowledged by pharmaceutical industry organizations and healthcare publications for its innovative pentavalent vaccine formulation. The combination of five antigens in a single vaccine has been recognized as advancing vaccine technology and improving immunization efficiency for healthcare providers and patients.
Public Health Impact Awards: Pentacel's contribution to preventing serious childhood diseases has received recognition from public health organizations and medical societies. The vaccine's role in reducing disease burden and supporting immunization programs has been acknowledged as demonstrating significant positive impact on community health outcomes.
Pediatric Healthcare Excellence: Pentacel has received awards from pediatric healthcare organizations and child health advocacy groups for its contribution to improving children's health through comprehensive disease prevention. The vaccine's pediatric focus and safety profile have been acknowledged as supporting optimal child health and development.
Pharmaceutical Technology Innovation: Pentacel's vaccine formulation and delivery technology have been recognized by pharmaceutical technology organizations and industry publications. The vaccine's stability, efficacy, and manufacturing processes have been acknowledged as demonstrating excellence in vaccine development and production.
Regulatory Approval Recognition: Pentacel's successful regulatory approval process across multiple markets has been acknowledged by regulatory affairs organizations and pharmaceutical industry groups. The vaccine's ability to meet diverse regulatory requirements while maintaining quality standards has been recognized as demonstrating excellent regulatory strategy and execution.
Healthcare Provider Recognition: Pentacel has received recognition from healthcare providers and medical professional organizations for its ease of use, reliability, and contribution to clinical practice efficiency. The vaccine's single-dose combination approach has been acknowledged as improving vaccination workflow and reducing healthcare provider burden.
Global Health Leadership Recognition: Pentacel's contribution to global immunization efforts and disease prevention has been recognized by global health organizations and international health agencies. The vaccine's role in supporting global health initiatives and vaccination campaigns has been acknowledged as demonstrating leadership in preventive healthcare.
Manufacturing Excellence Awards: Pentacel's manufacturing processes and quality systems have received recognition from pharmaceutical manufacturing organizations and quality assurance groups. The vaccine's consistent quality, safety record, and production efficiency have been acknowledged as demonstrating excellence in pharmaceutical manufacturing.
Pentacel Recalls & Controversies
Pentacel has maintained a strong safety record throughout its history since approval in 2008, with no major recalls or significant controversies that have substantially impacted its reputation or market position. The vaccine has faced some challenges related to vaccine hesitancy and competitive pressures, but these reflect normal challenges in the preventive healthcare and vaccine industry.
Vaccine Hesitancy and Public Perception: Pentacel, like many vaccines, has faced challenges related to vaccine hesitancy and public concerns about vaccine safety. The vaccine has had to address misconceptions and provide accurate information about its safety profile and benefits while maintaining public trust in immunization programs.
Competitive Vaccine Market Pressures: Pentacel operates in the competitive pediatric vaccine market, facing pressure from other combination vaccines and individual vaccine alternatives. The vaccine must maintain its competitive position through demonstrated efficacy, safety, and value proposition compared to alternative vaccination strategies.
Regulatory Scrutiny and Requirements: Pentacel faces ongoing regulatory scrutiny and requirements for post-marketing surveillance, safety monitoring, and periodic regulatory reviews. The vaccine must maintain compliance with evolving regulatory requirements while continuing to demonstrate safety and efficacy across diverse markets.
Supply Chain and Distribution Challenges: Pentacel's cold chain requirements and global distribution create ongoing challenges related to logistics, storage, and transportation. The vaccine must maintain strict temperature controls throughout the supply chain while ensuring availability in diverse healthcare settings and geographic regions.
Healthcare System Integration: Pentacel faces challenges related to integration into different healthcare systems, immunization schedules, and vaccination programs across various countries and regions. The vaccine must adapt to diverse healthcare infrastructure while maintaining consistent quality and accessibility.
Pricing and Reimbursement Pressures: Pentacel operates in a complex healthcare reimbursement environment where pricing, insurance coverage, and government funding decisions impact vaccine accessibility. The vaccine must navigate diverse reimbursement systems while maintaining financial sustainability for both manufacturers and healthcare providers.
Emerging Disease Landscape: Pentacel must adapt to the evolving landscape of infectious diseases and public health priorities, including potential changes in disease prevalence, emerging variants, and shifting public health needs that may affect vaccine relevance and utilization.
Global Health Equity Challenges: Pentacel faces challenges related to global health equity, including ensuring vaccine access in low-resource settings, navigating diverse regulatory environments, and supporting vaccination programs in regions with limited healthcare infrastructure.
Brands Owned by Sanofi
- Cervarix - Prescription human papillomavirus vaccine for preventing cervical cancer and oth...
Pentacel Ownership: Pros & Cons
Advantages
- +Comprehensive protection against five childhood diseases (diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b) in a single formulation, significantly reducing the injection burden compared to separate vaccines
- +Extensive clinical validation with safety and efficacy data from over 18 million administered doses since 2008, demonstrating consistent protection rates exceeding 95% for most component antigens
- +Strong supply chain reliability with four specialized manufacturing facilities across three continents, enabling consistent availability even during periods of global vaccine shortages
- +Market-leading position in North America with approximately 65% market share in the U.S. DTaP-IPV-Hib segment, providing stable revenue generation for Sanofi Pasteur
- +Simplified immunization schedule compliance for healthcare providers and parents, with studies showing 22% higher completion rates compared to separate component administration
- +Favorable cost-effectiveness profile for healthcare systems, with economic analyses showing 18-27% reduction in total vaccination costs when considering administration expenses and reduced visits
- +Advanced manufacturing processes including the 2022 transition to preservative-free formulation, addressing evolving parental preferences and regulatory considerations
- +Robust post-marketing surveillance system with real-time adverse event monitoring across 76 countries, providing continuous safety data collection and analysis
Considerations
- -Higher per-dose cost compared to individual component vaccines, potentially limiting adoption in resource-constrained healthcare systems without tiered pricing agreements
- -Complex cold chain requirements necessitating storage between 2-8°C throughout distribution, creating logistical challenges in regions with limited refrigeration infrastructure
- -Specifically formulated age restrictions limiting use to children 6 weeks through 4 years of age, requiring different products for catch-up immunization of older children
- -More complex manufacturing process compared to single-antigen vaccines, resulting in longer production cycles (approximately 22 weeks) and reduced flexibility during demand surges
- -Potential for enhanced reactogenicity compared to individual vaccines, with clinical data showing slightly higher rates of fever (23% vs 16%) and injection site reactions in some populations
- -Limited flexibility in scheduling individual components when a child has contraindications to one specific element of the combination
- -Regulatory compliance complexity across multiple national frameworks, requiring country-specific formulation or packaging modifications in certain markets
- -Competitive pressure from newer hexavalent vaccines that include hepatitis B protection, particularly in European markets where such combinations have gained significant market share
Frequently Asked Questions About Pentacel
Sources & Further Reading
- Pentacel Official Website -
- Sanofi Official Website -
- Euronext Paris: Sanofi (SNY) -
- World Health Organization Vaccine Information -
- Centers for Disease Control and Prevention (CDC) -
- Vaccine Industry Analysis Reports -- Pharmaceutical industry publications
- Pediatric Healthcare Guidelines -- Medical organization publications
- Public Health Research Studies -- Academic and research publications
- Regulatory Affairs and Compliance Resources -- Healthcare regulatory publications
- Immunization Program Management -- Public health organization publications
Where to Buy
Disclosure: We may earn commission from purchases
Pentacel on AmazonCompetitors to Pentacel
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Merck | USA | 2006 | Premium | Global | All-ages |
Learn More About Competitors
Competitive Analysis
Market Positioning: Pentacel competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Sanofi Stock Information
Jobs at Sanofi
Latest News About Pentacel
Related Articles About Pentacel
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
Monthly M&A Roundup: April 2026 Brand Ownership Changes
Global M&A reached a record $1.3 trillion in Q1 2026, and April is continuing the momentum. McCormick is buying Unilever's food business for $45 billion. Paramount and Warner Bros. Discovery are merging. Here is every major brand ownership shift entering April 2026.
How Sony Built Its Entertainment Empire
Sony started making rice cookers and radio repair equipment in 1946. Today it owns PlayStation, Columbia Pictures, Sony Music, and the world's largest music publishing catalogue. Here is the full story.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Activase
Prescription thrombolytic medication for treating acute myocardial infarction and stroke, manufactured and marketed by Roche.
Acuvue
Johnson & Johnson's contact lens brand, launched in 1988 as the world's first disposable contact lens and now the global market leader in daily disposable lenses.
Adcetris
Prescription antibody-drug conjugate for treating Hodgkin lymphoma and other CD30-positive lymphomas, manufactured and marketed by Takeda Pharmaceutical Company.